HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leiner To Bolster OTC Capabilities With Purchase of PFI Assets

This article was originally published in The Tan Sheet

Executive Summary

Private-labeler Leiner expects to significantly expand its OTC presence and market share with the proposed purchase of assets from Edison, N.J.-based Pharmaceutical Formulations, Inc. (PFI)

You may also be interested in...



Leiner OTC Sales Jump Nearly 30% On New Products, Manufacturing Promotions

Private labeler Leiner Health Products' OTC product sales increased by nearly 30% for its fiscal 2007 second quarter, driven largely by new product launches and promotions with manufacturing customers, COO Robert Reynolds said in a Nov. 14 analysts call

Leiner/PFI

Leiner Health Products completes its acquisition of "substantially all" assets related to Pharmaceutical Formulations' (PFI) "solid dose pharmaceutical products business" for $23 mil. in cash, Leiner announces Sept. 26. In addition to opportunities in pain management in both OTC and supplement areas, the acquisition "allows us to enhance our contract manufacturing capabilities and expands our OTC product offering and customer base," CEO Robert Kaminski says. Leiner concurrently announces that it has amended its credit agreement, which "will enhance the company's flexibility to manage the business and support the acquisition." Leiner's plans to acquire PFI's assets were made known shortly after the Edison, N.J.-based company declared bankruptcy in July (1"The Tan Sheet" July 18, 2005, p. 4)...

Leiner Looks For Ibuprofen Growth Following “Negative Mix Impact”

Increased ibuprofen opportunities from the planned acquisition of Pharmaceutical Formulations, Inc. (PFI) will help build Leiner's pain management category to $200 mil. by the end of the year, CEO Bob Kaminski claimed Aug. 10

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS126518

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel